ライフサイエンスコーパス: blood stem cell

1 they are engrafted with human umbilical cord blood stem cells.

2 l transplantation currently using peripheral blood stem cells.

3 354 after the transplantation of peripheral-blood stem cells.

4 esis for collection of autologous peripheral blood stem cells.

5 e engraftment of CD34(+) selected peripheral blood stem cells.

6 applications for IL-17-mobilized peripheral blood stem cells.

7 elated cord blood, and allogeneic peripheral blood stem cells.

8 iability without effect on normal peripheral blood stem cells.

9 owed by infusion of unmanipulated peripheral blood stem cells.

10 tation of ex vivo T-cell-depleted peripheral blood stem cells.

11 undertaken using G-CSF mobilized peripheral blood stem cells.

12 rted in transplant patients who receive cord blood stem cells.

13 ine signaling can instruct lineage choice in blood stem cells.

14 lso required for the formation of definitive blood stem cells.

15 filgrastim to mobilize autologous peripheral-blood stem cells.

16 increased the self-renewal of hematopoietic (blood) stem cells.

17 d-derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow-derived

18 nmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 x 10(6) cells/kg) from human

19 lignancies and causes the rapid attrition of blood stem cells(5-7).

20 RIC peripheral blood stem cell allo-HSCT is prospectively feasible for

21 ine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identical sibling

22 ) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation.

23 successive genetic and epigenetic events in blood stem cells also involves competition and selection

24 sults in successful collection of peripheral blood stem cells and allows flow rates comparable to tho

25 ion immune reconstitution between peripheral blood stem cells and bone marrow.

26 d 10/10 matched grafts or between peripheral blood stem cells and bone marrow.

27 and monocytes mirrors TL of CD34+ peripheral blood stem cells and progenitor cells extremely well (r=

28 ated to TL in CD34+ hematopoietic peripheral blood stem cells and progenitor cells obtained from the

29 ifference was identical for CD34+ peripheral blood stem cells and progenitor cells, monocytes, granul

30 blood cell populations, including peripheral blood stem cells and progenitor cells.

31 ng factor (G-CSF) mobilization of peripheral blood stem cells and retrovirus transduction using hemat

32 e mesoderm, and contains precursors of adult blood stem cells and the major vessels.

33 Mutant fish engraft muscle, blood stem cells and various cancers.

34 cant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unr

35 of several tissues, is a master regulator of blood stem cells, and plays a role in leukemia.

36 Most (92%) received blood stem cells, and the remainder received bone marrow

37 unrelated donor, matched-sibling peripheral blood stem cells, and unrelated cord blood.

38 Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of

39 Mobilized peripheral blood stem cells are increasingly used for the reconstit

40 lony-stimulating factor-mobilized peripheral blood stem cells are widely used to reconstitute hematop

41 hed frequently from intermittently activated blood stem cells, are short-lived in vivo and may contai

42 uced-intensity conditioning using peripheral blood stem cells as the source of the graft and PTCy as

43 teristic of the malignant differentiation of blood stem cells based on studies of alterations that af

44 ysis including patients receiving peripheral blood stem cells, being in complete remission, or receiv

45 otential of human bone marrow and peripheral blood stem cells, blood vessels in sex-mismatched transp

46 of evaluable related bone marrow/peripheral blood stem cells (BM/PBSCs), unrelated BM/PBSCs, and unr

47 colony-stimulating factor (G-CSF)-mobilized blood stem cell (BSC) harvests from 104 healthy donors w

48 imulating factor (G-CSF) mobilize peripheral blood stem cells by different mechanisms.

49 d X-CGD patient-mobilized CD34(+) peripheral blood stem cells (CD34(+)PBSCs) with lentivector-gp91(ph

50 ater showed that transduced CD34+ peripheral blood stem cells (CD34+ PBSCs) from this trial transplan

51 t not with donor age, graft type (marrow vs. blood stem cells), CD34 cell dose, conditioning (with vs

52 ge colony-stimulating factor with peripheral blood stem cell collection, and etoposide-dexamethasone-

53 Peripheral-blood stem-cell collection was performed after the secon

54 eatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatro

55 Analysis of peripheral-blood stem-cell collections by molecular techniques for

56 Three peripheral blood stem cell concentrates were collected from 3 macaq

57 ntigen (HLA)-matched related (MR) peripheral blood stem cells conferred protection against early IA c

58 g factor (G-CSF)-mobilized, CD34+ peripheral blood stem cells derived from a patient with the severe

59 Blood stem cells develop at successive sites in the vert

60 ly regulates vegfa expression during Xenopus blood stem cell development through multiple transcripti

61 Donor Program (NMDP) in promoting unrelated blood stem-cell donation are addressed.

62 lony-stimulating factor-mobilized peripheral blood stem cell donor grafts and successful treatment of

63 cell dose, type of transplant (marrow versus blood stem cells), donor age, or patient age.

64 surface protein expression for selection of blood stem cell donors.

65 reached on safety considerations for healthy blood stem cell donors.

66 When human blood stem cells engineered to carry DC-causing PARN mut

67 Starting with a well-characterized blood stem cell enhancer from the SCL gene, we have deve

68 It has been generally held that mobilized blood stem cells express CD34.However, it has also been

69 sed as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell trans

70 essary to definitively establish the role of blood stem cells for allogeneic transplantation, especia

71 ine the feasibility of collecting peripheral blood stem cells for future use.

72 w regulates vascular remodelling, stimulates blood stem cell formation, and has a role in the patholo

73 Peripheral blood stem cells from 2 rhesus monkeys were collected, C

74 lantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates

75 Unmanipulated bone marrow or peripheral blood stem cells from HLA-matched related-donors or HLA-

76 ning regimens using unmanipulated peripheral blood stem cells from human leukocyte antigen (HLA)-comp

77 Forty-two adult recipients of allogeneic blood stem cells from human leukocyte antigen-matched re

78 arrow cells or cytokine-mobilized peripheral blood stem cells from leukocyte antigen-matched animals

79 splanted each year worldwide using marrow or blood stem cells from unrelated volunteers.

80 ell biology and a promising method for human blood stem cell gene therapy.

81 nt information about the basic mechanisms of blood stem cell generation, expansion, and migration.

82 Haematopoiesis is the process whereby blood stem cells give rise to at least fourteen function

83 mor cells from the bone marrow or peripheral blood stem cell graft without causing stem cell damage t

84 CD34+33- cell quantity of the blood stem-cell graft appears to be a more reliable pred

85 lony-stimulating factor-mobilized peripheral blood stem cell grafts (naive and memory T-cell subsets,

86 Allogeneic peripheral blood stem cell grafts contain about 10 times more T and

87 Because unmodified blood stem cell grafts contain one log more T lymphocyte

88 quantity of hematopoietic progenitors in the blood stem cell grafts from filgrastim-stimulated donors

89 eas recipients of T cell-depleted peripheral-blood stem cell grafts had 28-fold and 14-fold lower CD4

90 HLA-matched donor bone marrow or peripheral blood stem cell grafts to reconstitute haematopoiesis an

91 A total of 20 peripheral blood stem cell grafts were analyzed, and donors were cl

92 Autologous peripheral blood stem cell grafts were CD34+ selected; the particip

93 lowed by reinfusion of autologous peripheral blood stem cells; group E).

94 ecipients of plerixafor mobilized peripheral blood stem cells had a significantly higher incidence of

95 for 7 days and autologous CD34(+) peripheral blood stem cells harvested by leukapheresis.

96 and more cost-effective, than typical BM or blood stem cell harvesting.

97 n bone marrow and mobilized human peripheral blood stem cell harvests.

98 rd blood banking and transplantation of cord blood stem cells has advanced rapidly over the initial 2

99 ugh the use of cytokine-mobilized peripheral blood stem cells has gained a significant momentum in cl

100 Human cord blood stem cells (hCBSCs) have been reported to generate

101 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation (URD-

102 lant conditioning, and the use of peripheral blood stem cells in hematopoietic cell transplantation (

103 and erythroid differentiation of peripheral blood stem cells in liquid culture.

104 in swine, by using high doses of peripheral blood stem cells in the absence of WBI.

105 nt recipients for a long time, recipients of blood stem cells may be less immunocompromised than reci

106 condary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, w

107 tation of unmanipulated filgrastim-mobilized blood stem cells may result in a relatively high inciden

108 uction therapy and then underwent peripheral blood stem-cell mobilisation and harvesting if applicabl

109 filed in murine and rhesus monkey peripheral blood stem cell mobilization and transplantation models.

110 enhancing its myeloprotective or peripheral blood stem cell mobilization properties, which can be us

111 y transplant studies in mice, and peripheral blood stem cells mobilized by AMD3100 and granulocyte co

112 lative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte colony-stimul

113 T cells from CD34-enriched human peripheral blood stem cells modified with a lentiviral vector desig

114 promote human B cell development in the cord blood stem cell/MS-5 culture, we made the unexpected fin

115 bited development of CD19+ cells in the cord blood stem cell/MS-5 culture.

116 -lineage cells purified from xenogeneic cord blood stem cell/MS-5 murine stromal cell cultures, to fu

117 We used a xenogeneic human cord blood stem cell/murine stromal cell culture to study the

118 rphologically normal BM (n = 22), peripheral blood stem cells (n = 10) from patients with cancers oth

119 The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11).

120 lony stimulating factor mobilized peripheral blood stem cells (n = 4), and a VCA transplant from the

121 (n=8) or ex vivo T-cell-depleted peripheral blood stem cells (n=4) for chemorefractory hematologic m

122 d an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched rel

123 bition on sale did not encompass "peripheral blood stem cells" obtained through apheresis.

124 rtalised erythroid cell line from peripheral blood stem cells of a HbE/beta-thalassemia patient.

125 ce of megakaryocytes derived from peripheral blood stem cells of GT patients.

126 rapeutic regimens with autologous peripheral blood stem cell or allogeneic bone marrow rescue are rig

127 VHD), a common complication after peripheral blood stem cell or bone marrow transplantation, rarely o

128 Support with peripheral blood stem cells or bone marrow and with granulocyte col

129 Autologous peripheral-blood stem cells or bone marrow were infused on day 0.

130 ndomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratifi

131 chemotherapy alone (P = .006), marrow versus blood stem cell (P = .01), serum ALT greater than 50 IU/

132 study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by tra

133 ociated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelated voluntee

134 by 2726 bone marrow (BM) and 6768 peripheral blood stem cell (PBSC) donors who underwent collection o

135 We studied whether peripheral blood stem cell (PBSC) graft iNKT-cell dose affects on t

136 Unfractionated peripheral blood stem cell (PBSC) grafts contain measurable quantit

137 etion of TN from human allogeneic peripheral blood stem cell (PBSC) grafts would reduce GVHD and prov

138 Peripheral-blood stem cell (PBSC) harvest and surgical resection of

139 elotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion.

140 Peripheral blood stem cell (PBSC) infusions are associated with com

141 ate the safety and feasibility of peripheral blood stem cell (PBSC) mobilization in 8 SCT subjects an

142 A reliable estimate of peripheral blood stem cell (PBSC) mobilization response to granuloc

143 High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the tre

144 b), combined with doxorubicin and peripheral blood stem cell (PBSC) support in advanced medullary thy

145 host-reactive donor T cells from peripheral blood stem cell (PBSC) transplant allografts ex vivo usi

146 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical

147 Peripheral blood stem cell (PBSC) transplantation is successful in

148 Peripheral blood stem cell (PBSC) transplantation may provide a str

149 myeloablative versus conventional peripheral blood stem cell (PBSC) transplants from HLA-matched sibl

150 tropenic recipients of autologous peripheral blood stem cell (PBSC) transplants.

151 Autologous peripheral blood stem cell (PBSC)-supported high-dose melphalan is

152 Currently, peripheral blood stem cells (PBSC) are infused after myeloablative

153 ant cyclophosphamide (PTCY) using peripheral blood stem cells (PBSC) as a source of graft.

154 which is widely used to mobilize peripheral blood stem cells (PBSC) from normal donors, has led to t

155 Recipients of peripheral blood stem cells (PBSC) had faster recovery and fewer pl

156 Peripheral blood stem cells (PBSC) have become the preferred source

157 Peripheral-blood stem cells (PBSC) may be used as an alternative to

158 h autologous SCT, currently using peripheral blood stem cells (PBSC) mobilized by chemotherapy and re

159 Peripheral blood stem cells (PBSC) obtained from granulocyte-colony

160 Autologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic

161 Human peripheral blood stem cells (PBSC) were obtained by leukapheresis f

162 f 18 at level II received BM plus peripheral-blood stem cells (PBSC).

163 periences of 69 (38 marrow and 31 peripheral blood stem cell [PBSC]) donors participating in a random

164 rrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients.

165 in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy.

166 Mobilized peripheral blood stem cells (PBSCs) are widely used for transplanta

167 atelet development in which human peripheral blood stem cells (PBSCs) differentiate along megakaryocy

168 Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, an

169 Two patients received peripheral blood stem cells (PBSCs) from matched-related donors, 2

170 Peripheral blood stem cells (PBSCs) have been widely adopted as a s

171 Although peripheral blood stem cells (PBSCs) have replaced bone marrow (BM)

172 he majority of the most primitive peripheral blood stem cells (PBSCs) in PNH appear to be of normal p

173 lating factor (G-CSF) to mobilize peripheral blood stem cells (PBSCs) is increasing.

174 chemotherapy (HDC) supported with peripheral-blood stem cells (PBSCs) is related to the dose of CD34(

175 on with syngeneic plus allogeneic peripheral blood stem cells (PBSCs) is sufficient to interrupt auto

176 se chemotherapy, patients who had peripheral-blood stem cells (PBSCs) mobilized with filgrastim or th

177 , 609 recipients of HLA-identical peripheral-blood stem cells (PBSCs), and 675 recipients of unrelate

178 preferred source of the graft was peripheral blood stem cells (PBSCs).

179 onuclear cells (PBMCs), and CD34+ peripheral blood stem cells (PBSCs).

180 lated donor transplant from BM or peripheral blood stem cells (PBSCs).

181 by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49).

182 rce of stem cells (bone marrow vs peripheral blood stem cells [PBSCs]), age, sex, graft-versus-host d

183 r frequency in pre-HCT marrow and peripheral-blood stem cells predicted for primitive progenitor reco

184 h Fanconi anemia is collection of peripheral blood stem cells prior to the development of severe panc

185 identical related donors, and umbilical cord blood stem cell products are frequently used when a well

186 e DA roof, a ventral Bmp4 signal induces the blood stem cell program in the DA floor.

187 wine using a high-dose allogeneic peripheral blood stem cell protocol.

188 ma(null) mice engrafted with human mobilized blood stem cells provide a new in vivo long-lived model

189 lony-stimulating factor-mobilized autologous blood stem cells provided hematopoietic rescue.

190 ransplantation in 9 marrow recipients and no blood stem cell recipients (P =.008).

191 ce of chronic GVHD in previously reported 37 blood stem cell recipients and 37 computer-matched histo

192 2 years posttransplant among the peripheral blood stem cell recipients compared with the marrow reci

193 Blood stem cell recipients did not have higher antibody

194 In conclusion, blood stem cell recipients have higher lymphocyte-subset

195 f most lymphocyte subsets were higher in the blood stem cell recipients.

196 s and transfusion requirements in autologous blood stem-cell recipients.

197 d transcriptional enhancer elements with the blood stem cell regulator TAL1/SCL.

198 ype-specific binding and (iii) knock-down of blood stem cell regulators in mast cells reveals mast ce

199 zed protein-protein interactions between key blood stem cell regulators.

200 es of high-dose chemotherapy with peripheral blood stem cell rescue and involved-field radiation ther

201 py with autologous bone marrow or peripheral blood stem cell rescue is one of the most aggressive tre

202 tandem high-dose chemotherapy and peripheral-blood stem-cell rescue and local irradiation, and sugges

203 tepa and etoposide and autologous peripheral blood stem-cell rescue before craniospinal irradiation.

204 cycles of high-dose therapy with peripheral-blood stem-cell rescue followed by radiation to the prim

205 cycles of high-dose therapy with peripheral blood stem-cell rescue, local radiotherapy, and 13-cis-r

206 e cycles of high-dose therapy and peripheral-blood stem-cell rescue, two patients completed two cycle

207 cycles of high-dose therapy with peripheral blood stem-cell rescue.

208 mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice.

209 ustine (RR = 2.3) and with use of peripheral blood stem cells (RR = 2.4).

210 The prognostic importance of peripheral blood stem cell source in critically ill HSCT recipients

211 silencing to non-canonical functions during blood stem cell specification.

212 erved, pretransplant bone marrow, peripheral blood stem cell specimens, obtained at the time of harve

213 dose melphalan-based therapy with peripheral blood stem cell support and, hence, should not constitut

214 or growth factor mobilization and peripheral blood stem cell support compared with bone marrow transp

215 herapy with either bone marrow or peripheral blood stem cell support.

216 strated dramatic expansion of umbilical cord blood stem cells that promote rapid engraftment while ma

217 onors, 4) increasing the yield of peripheral blood stem cells through synergy with other hematopoieti

218 Sufficient peripheral blood stem cells to support two HDT cycles (CD34 > 5 x 1

219 tubated patients, those receiving peripheral blood stem cell transplant (PBSCT) had significantly bet

220 ents who had received a marrow or peripheral blood stem cell transplant from an HLA-identical sibling

221 nt Enterococcus faecalis infection in a cord blood stem cell transplant recipient previously treated

222 cutive series of 116 evaluable HLA-identical blood stem cell transplant recipients.

223 ity and achieve engraftment of an allogeneic blood stem cell transplant, allowing a graft-versus-mali

224 ve the utility and convenience of peripheral blood stem cell transplant.

225 hal case of pneumonia following a peripheral blood stem cell transplant.

226 lony stimulating-factor-mobilized peripheral-blood stem-cell transplant from his HLA-identical brothe

227 med a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to exploit a

228 chronic GVHD was significantly higher after blood stem cell transplantation (1-year probability [95%

229 Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) is a common

230 herapy with or without autologous peripheral blood stem cell transplantation (APBSCT).

231 Blood stem cell transplantation (BSCT) results in rapid

232 emotherapy followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can produce he

233 halan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been deve

234 tution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id i

235 High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associa

236 oved response rates observed with peripheral blood stem cell transplantation (PBSCT) in patients with

237 Allogeneic peripheral blood stem cell transplantation (PBSCT) is increasingly

238 Peripheral blood stem cell transplantation (PBSCT) is the most comm

239 icenter phase III trial comparing peripheral blood stem cell transplantation (PBSCT) to bone marrow t

240 is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selecti

241 is of patients with AL undergoing peripheral blood stem cell transplantation (PBSCT).

242 rgoing high-dose chemotherapy and peripheral blood stem cell transplantation (PSCT).

243 High-dose melphalan with autologous blood stem cell transplantation (SCT) can reverse the di

244 tion to hospital discharge was 23 days after blood stem cell transplantation and 28 days after bone m

245 y JC papovavirus after autologous peripheral blood stem cell transplantation and a case each of cytom

246 ute to inferior platelet recovery after cord blood stem cell transplantation and may underlie ineffic

247 roid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in

248 ith autologous and allogeneic bone marrow or blood stem cell transplantation appear to induce a prolo

249 d recovery of hematopoiesis after allogeneic blood stem cell transplantation has been attributed to t

250 0(4) T cells/kg) nonmyeloablative peripheral blood stem cell transplantation in children and young ad

251 Peripheral blood stem cell transplantation is being used more frequ

252 NCA (131)I-MIBG with autologous peripheral blood stem cell transplantation is feasible at 666 MBq/k

253 dministration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neu

254 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this t

255 ymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients with advanc

256 Two days before allogeneic peripheral blood stem cell transplantation, miniature swine were co

257 chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors m

258 (2) intravenously) and autologous peripheral blood stem cell transplantation, with marked improvement

259 g rituximab from the early 2000s followed by blood stem cell transplantation.

260 ions of allogeneic bone marrow or peripheral blood stem cell transplantation.

261 er allogeneic marrow or filgrastim-mobilized blood stem cell transplantation.

262 risk factors for acute GVHD after allogeneic blood stem cell transplantation.

263 py, whole-brain radiotherapy, and peripheral blood stem cell transplantation.

264 ent infection in encephalitis following cord blood stem cell transplantation.

265 RIC unrelated adult donor or umbilical cord blood stem cell transplantation.

266 tion (ABMT) (n = 46) or mobilized peripheral-blood stem-cell transplantation (PBSCT) (n = 47).

267 high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at Indiana Unive

268 disease (GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when compared wi

269 ho underwent autologous marrow or peripheral-blood stem-cell transplantation at our institution betwe

270 c granulomatous disease underwent peripheral-blood stem-cell transplantation from an HLA-identical si

271 nic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical si

272 ensive intravenous melphalan with autologous blood stem-cell transplantation improves the nephrotic s

273 ensive intravenous melphalan with autologous blood stem-cell transplantation induces remission of the

274 oplatin and etoposide followed by peripheral-blood stem-cell transplantation or autologous bone marro

275 sus-host disease after allogeneic peripheral blood stem-cell transplantation who had severe refractor

276 who would have been eligible for peripheral-blood stem-cell transplantation.

277 ns of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

278 ompared results of 288 HLA-identical sibling blood stem cell transplantations with results of 536 HLA

279 Recipients of blood stem cell transplants had more rapid recovery of n

280 eukemia-free survival rates were higher with blood stem cell transplants in patients with advanced le

281 ata from 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007

282 adult recipients of HLA-identical allogeneic blood stem cell transplants.

283 bolites in patients who underwent peripheral-blood stem-cell transplants.

284 metabolites in patients following peripheral-blood stem-cell transplants; (2) allow consideration of

285 ts the concept that the mobilized peripheral blood stem cells used in clinical transplantation functi

286 in, CD34-selected, c-kit(+) human peripheral blood stem cells using a c-kit-targeted adenovirus vecto

287 mized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donor

288 Peripheral blood stem cells were associated with a nonsignificant i

289 Peripheral blood stem cells were collected from responding patients

290 Sufficient numbers of peripheral-blood stem cells were collected in all but one patient.

291 CD34+ cord blood stem cells were cultured on the MS-5 murine stroma

292 Unselected peripheral blood stem cells were harvested with cyclophosphamide (2

293 Peripheral blood stem cells were mobilized with cyclophosphamide (2

294 Peripheral blood stem cells were mobilized with cyclophosphamide an

295 er induction therapy and surgery, peripheral-blood stem cells were mobilized with three cycles of hig

296 f ATG used, and CD34-selection of peripheral blood stem cells were not found to be significantly asso

297 whereas HLA-matched sibling donor peripheral blood stem cells were significantly worse (25%, 95% CI 2

298 Peripheral blood stem cells were the stem cell source in 68% of pat

299 cells, developed in vitro from CD34(+) cord blood stem cells, were experimentally infected with the

300 ies were randomized to receive marrow versus blood stem cells, which contain approximately 10 times m